Anixa Biosciences, Inc. (ANIX)
ANIX moved a median of 0.00% 30 minutes after news, and -0.29% by the close. How ANIX actually reacts to news — the realized, point-in-time move the market made, measured across 217 labeled events over the last three years with zero look-ahead.
ANIX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 38% | 210 |
| 30-min | 0.00% | 49% | 216 |
| 60-min | -0.07% | 45% | 217 |
| to close | -0.29% | 44% | 216 |
| Middle 50% of ANIX reactions | -1.24% to +1.43% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 217 |
Half of all Anixa Biosciences, Inc. news events land between -1.24% and +1.43% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ANIX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ANIX's baseline. Nothing else.
Recent ANIX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference | Press release | PR Newswire | +0.00% | -5.99% | |
| Join Anixa Biosciences' Live Investor Webinar: Advancing Innovative CAR-T Therapy for Ovarian Cancer and a First-in-Class Breast Cancer Vaccine | Press release | ACCESS Newswire | +0.00% | -5.99% | |
| Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial | Press release | PR Newswire | -3.02% | -1.01% | |
| Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial | Press release | PR Newswire | -1.36% | -5.46% | |
| Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040 | Press release | PR Newswire | -2.13% | -4.25% | |
| Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board | Press release | PR Newswire | -1.48% | -3.70% | |
| Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV | Press release | ACCESS Newswire | -1.04% | -3.83% | |
| Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV | Press release | PR Newswire | -1.37% | -3.08% | |
| Form 10-Q Anixa Biosciences Inc For: Jul 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.31% | -0.36% | |
| Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026 | Press release | PR Newswire | +1.59% | -2.87% | |
| Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy | Press release | PR Newswire | -0.82% | -1.09% | |
| Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference | Press release | PR Newswire | +0.88% | +0.59% | |
| Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology | Press release | PR Newswire | +1.15% | +4.93% | |
| Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date | Press release | PR Newswire | +0.13% | -3.17% | |
| Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040 | Press release | PR Newswire | -4.73% | +1.79% | |
| Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium | Press release | PR Newswire | -8.72% | +7.31% | |
| Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium | Press release | PR Newswire | +3.42% | +5.98% | |
| Form 10-Q Anixa Biosciences Inc For: Apr 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.42% | +5.98% | |
| Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance | Press release | PR Newswire | -0.37% | -0.37% | |
| Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy | Press release | PR Newswire | -0.66% | +0.66% | |
| Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV | Press release | PR Newswire | +0.33% | +5.02% | |
| Anixia Biosciences and OwlTing Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV | Press release | ACCESS Newswire | +0.33% | +5.02% | |
| Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology | Press release | PR Newswire | -0.66% | -4.64% | |
| Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting | Press release | PR Newswire | +0.34% | +6.80% | |
| RedChip's April 16 Virtual Investor Conference to Highlight Companies Driving the Next Wave of Biotech Innovation | Press release | ACCESS Newswire | +0.00% | -0.37% | |
| Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026 | Press release | PR Newswire | -0.37% | +1.11% | |
| Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026 | Press release | PR Newswire | +0.00% | +1.13% | |
| Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs | Press release | PR Newswire | +2.16% | +1.57% | |
| Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing | Press release | PR Newswire | -0.35% | +3.42% | |
| Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer | Press release | PR Newswire | +1.18% | -1.96% | |
| Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast | Press release | PR Newswire | -0.35% | +0.00% | |
| Form 8-K Anixa Biosciences Inc For: Mar 10 | SEC filing · Form 8-K | SEC EDGAR | +4.48% | -1.38% | |
| Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology | Press release | PR Newswire | +0.26% | +3.47% | |
| Form 10-Q Anixa Biosciences Inc For: Jan 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.66% | -1.00% | |
| Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress | Press release | PR Newswire | -0.35% | +2.78% | |
| Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat | Press release | PR Newswire | +4.89% | +2.45% | |
| Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation | Press release | PR Newswire | -4.87% | -0.33% | |
| Form 8-K Anixa Biosciences Inc For: Feb 09 | SEC filing · Form 8-K | SEC EDGAR | -4.87% | -0.33% | |
| Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization | Press release | PR Newswire | -2.64% | -2.97% | |
| Form DEF 14A Anixa Biosciences Inc For: Jan 28 | SEC filing · Form DEF | SEC EDGAR | -1.12% | -0.64% | |
| Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology | Press release | PR Newswire | -0.97% | -0.32% | |
| Form 10-K Anixa Biosciences Inc For: Oct 31 | SEC filing · Form 10-K | SEC EDGAR | -0.78% | +2.50% | |
| Form S-8 Anixa Biosciences Inc | SEC filing · Form S-8 | SEC EDGAR | -0.78% | +2.50% | |
| Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic | Press release | PR Newswire | -3.06% | -9.19% | |
| Form 8-K Anixa Biosciences Inc For: Dec 11 | SEC filing · Form 8-K | SEC EDGAR | -3.80% | -28.40% | |
| Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants | Press release | PR Newswire | -3.80% | -28.40% | |
| Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025 | Press release | PR Newswire | -2.37% | +1.18% | |
| Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization | Press release | PR Newswire | +0.24% | +2.44% | |
| Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s | Press release | PR Newswire | -2.63% | -3.94% | |
| Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025 | Press release | PR Newswire | +0.00% | -2.67% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ANIX section they belong to.
Where else ANIX is measured.
ANIX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Mettler-Toledo International, Inc. (MTD) | 219 | -0.10% | 39% |
| AngioDynamics, Inc. (ANGO) | 218 | +0.33% | 54% |
| Entera Bio Ltd. - Ordinary Shares (ENTX) | 217 | 0.00% | 46% |
| Precipio, Inc. (PRPO) | 217 | +0.51% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Anixa Biosciences, Inc.'s median reaction calculated?
Every labeled ANIX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 217 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 49% of ANIX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ANIX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.